BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

JX-594: Interim Phase II data

Interim data from 7 evaluable patients in a Phase II trial showed that IV and intratumoral doses of JX-594 followed by Nexavar sorafenib produced 1 partial response and 5 cases of stable disease as measured by RECIST criteria, with 6 patients achieving Choi necrotic...

Read the full 204 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >